15 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 8 Phase 2, 5 Phase 3, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 4, Recruiting 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Eye Infections, Parasitic: new trials by email Literature Review of Eye Infections, Parasitic trials Research Report on Eye Infections, Parasitic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Modified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg - Onchocerciasis (River Blindness), Schistosomiasis | Not applicable | Recruiting | Uwemedimo Friday Ekpo | 5760 | 2026-07-01 | 2026-07-16 |
| Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain. PHMB 0.08% - Acanthamoeba Keratitis | Completed | SIFI SpA | 23 | 2025-10-30 | 2026-06-22 | |
| Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/ml Polihexanide Acanthamoeba Keratitis | Completed | SIFI SpA | 40 | 2024-09-30 | 2025-10-01 | |
| Parasitic Ulcer Treatment Trial Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo - Acanthamoeba Keratitis | Phase 3 | Recruiting | Jeremy Keenan, MD, MPH | 232 | 2024-07-01 | 2026-10-01 |
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| Acanthamoeba and Artificial Intelligence Acanthamoeba Keratitis, Artificial Intelligence | Unknown | IRCCS Ospedale San Raffaele | 151 | 2024-05-01 | 2024-05-10 | |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction Moxifloxacin Ophthalmic, Chlorhexidine Gluconate, Natamycin - Acanthamoeba Keratitis, Fungal Keratitis | Phase 3 | Completed | University of California, San Francisco | 330 | 2022-08-03 | 2026-09-03 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 255 | 2021-01-16 | 2021-09-20 |
| Parasitic Ulcer Treatment Trial Pilot Chlorhexidine, Povidone-Iodine, Prednisolone Sodium Phosphate - Acanthamoeba Keratitis | Phase 2 | Completed | University of California, San Francisco | 49 | 2018-01-01 | 2026-05-07 |
| Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis PHMB 0.08%, Propamidine 0.1%, placebo - Acanthamoeba Keratitis | Phase 3 | Completed | SIFI SpA | 135 | 2017-08-13 | 2023-08-22 |
| Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures Ultrahigh resolution Spectral Domain OCT - Meibomian Gland Dysfunction, Cataract | Not applicable | Completed | Medical University of Vienna | 14 | 2017-07-12 | 2025-05-23 |
| Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects 0.04% PHMB, 0.06% PHMB, 0.08% PHMB - Acanthamoeba Keratitis | Phase 1 | Completed | SIFI SpA | 90 | 2015-11-01 | 2017-02-09 |
| Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years no intervention - Acanthamoeba Keratitis | Unknown | National Taiwan University Hospital | 100 | 2014-01-01 | 2016-05-09 | |
| Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Trimethoprim-Sulfamethoxazole - Ocular Toxoplasmosis | Phase 3 | Completed | University of Campinas, Brazil | 141 | 2011-10-01 | 2016-07-12 |
| Pediatric Pharmacokinetics And Safety Study Of Moxidectin moxidectin - Onchocerciasis | Phase 2 | Withdrawn | Pfizer | 2011-04-01 | 2012-03-29 | |
| Immunoblotting and Goldmann-Witmer Coefficient for Ocular Toxoplasmosis Aqueous humour sampling - Ocular Toxoplasmosis | Completed | Hospices Civils de Lyon | 87 | 2010-01-01 | 2019-05-14 |
Showing 20 of 23. Sign in to see all of them.
Acanthamoeba Keratitis (10) · Onchocerciasis, Ocular (10) · Onchocerciasis (8) · Toxoplasmosis, Ocular (3) · Loiasis (2) · Neglected Diseases (2) · Aniridia (1) · Cataract (1) · Chorioretinitis (1) · Corneal Ulcer (1) · Elephantiasis, Filarial (1) · Filariasis (1) · Glaucoma (1) · Helminthiasis (1) · Infections (1)
Eye Diseases (23) · Eye Infections (23) · Infections (22) · Parasitic Diseases (22) · Protozoan Infections (13) · Amebiasis (10) · Corneal Diseases (10) · Secernentea Infections (10) · Spirurida Infections (10) · Vector Borne Diseases (10) · Filariasis (9) · Helminthiasis (9) · Keratitis (9) · Nematode Infections (9)
Ivermectin (6) · moxidectin (5) · Albendazole (3) · polihexanide (3) · Bay 44-4400 (2) · Adrenal Cortex Hormones (1) · Chlorhexidine (1) · Corneal Cross-Linking (1) · Diethylcarbamazine (1) · Hypromellose Derivatives (1) · Levamisole (1) · Mass Drug Administration (1) · Mebendazole (1) · Natamycin (1) · Povidone-Iodine (1)
SIFI SpA (4) · Medicines Development for Global Health (2) · University of California, San Francisco (2) · AbbVie (1) · Bayer (1) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1) · Drugs for Neglected Diseases (1) · Hospices Civils de Lyon (1) · IRCCS Ospedale San Raffaele (1) · Jeremy Keenan, MD, MPH (1) · Medical University of Vienna (1) · National Taiwan University Hospital (1) · Pfizer (1) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (1) · University of Campinas, Brazil (1)
Brazil (3) · Democratic Republic of the Congo (3) · Ghana (3) · India (3) · Italy (2) · Liberia (2) · United Kingdom (2) · Austria (1) · Cameroon (1) · France (1) · Germany (1) · Nigeria (1) · Poland (1) · Republic of the Congo (1) · Spain (1)
Gary Weil, MD (1) · Gerami Seitzman, MD (1) · Hammed Mogaji, PhD (1) · Jennifer Rose-Nussbaumer, MD (1) · Jeremy D Keenan, MD (1) · Jeremy Keenan, MD, MPH (1) · John Dart, MD (1) · Karl Knutsson, MD (1) · Nicholas Opoku, MD (1) · Nicole Varnado, MPH (1) · Patrick Kpanyen, PhD (1) · Peter Fischer, PhD (1)
PMID 12095806, PMID 24968000, PMID 29361335, PMID 33239413, PMID 34651190, PMID 35476631, PMID 37802392, PMID 38966851, PMID 39011096, PMID 39192339, PMID 41561665, PMID 41914638, PMID 42141248, PMID 42348235
2023 (1), UG1EY028518 (1), UG1EY033284 (1)